Duyuru • Jun 04
Synthaverse S.A., Annual General Meeting, Jun 29, 2026 Synthaverse S.A., Annual General Meeting, Jun 29, 2026, at 12:00 Central European Standard Time. New Risk • Mar 30
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. High level of non-cash earnings (36% accrual ratio). Minor Risk Market cap is less than US$100m (zł254.8m market cap, or US$68.5m). New Risk • Oct 13
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 36% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). High level of non-cash earnings (36% accrual ratio). Minor Risk Market cap is less than US$100m (zł297.6m market cap, or US$80.9m). Reported Earnings • Oct 06
Second quarter 2025 earnings released: zł0.059 loss per share (vs zł0.02 profit in 2Q 2024) Second quarter 2025 results: zł0.059 loss per share (down from zł0.02 profit in 2Q 2024). Revenue: zł6.29m (down 59% from 2Q 2024). Net loss: zł4.77m (down 437% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. New Risk • Sep 22
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 36% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). High level of non-cash earnings (36% accrual ratio). Minor Risk Market cap is less than US$100m (zł306.4m market cap, or US$84.5m). Duyuru • Aug 26
Synthaverse S.A. to Report First Half, 2025 Results on Sep 30, 2025 Synthaverse S.A. announced that they will report first half, 2025 results on Sep 30, 2025 Reported Earnings • Nov 21
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: zł13.4m (up 65% from 3Q 2023). Net loss: zł444.0k (loss narrowed 82% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 12% per year. Reported Earnings • Sep 26
Second quarter 2024 earnings released: EPS: zł0.011 (vs zł0.037 in 2Q 2023) Second quarter 2024 results: EPS: zł0.011 (down from zł0.037 in 2Q 2023). Revenue: zł15.2m (down 17% from 2Q 2023). Net income: zł1.42m (down 45% from 2Q 2023). Profit margin: 9.3% (down from 14% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings. Duyuru • May 31
Synthaverse S.A., Annual General Meeting, Jun 25, 2024 Synthaverse S.A., Annual General Meeting, Jun 25, 2024. Reported Earnings • May 23
First quarter 2024 earnings released First quarter 2024 results: Revenue: zł13.9m (up 16% from 1Q 2023). Net loss: zł394.0k (down 153% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Apr 19
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to zł5.07, the stock trades at a trailing P/E ratio of 75.1x. Average trailing P/E is 32x in the Biotechs industry in Europe. Total loss to shareholders of 55% over the past three years. Reported Earnings • Apr 11
Full year 2023 earnings released: EPS: zł0.07 (vs zł0.093 in FY 2022) Full year 2023 results: EPS: zł0.07 (down from zł0.093 in FY 2022). Revenue: zł58.6m (up 16% from FY 2022). Net income: zł4.76m (down 22% from FY 2022). Profit margin: 8.1% (down from 12% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 26
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: zł8.10m (down 40% from 3Q 2022). Net loss: zł2.42m (down 257% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 21
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: zł18.4m (up 31% from 2Q 2022). Net income: zł2.57m (down 6.1% from 2Q 2022). Profit margin: 14% (down from 20% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings. Duyuru • May 27
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 22, 2023 BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 22, 2023, at 11:00 Central European Standard Time. Reported Earnings • Apr 21
Full year 2022 earnings released Full year 2022 results: Revenue: zł50.4m (up 22% from FY 2021). Net income: zł6.08m (up 43% from FY 2021). Profit margin: 12% (up from 10% in FY 2021). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Dec 01
Investor sentiment deteriorated over the past week After last week's 19% share price decline to zł5.70, the stock trades at a trailing P/E ratio of 56.6x. Average trailing P/E is 49x in the Biotechs industry in Poland. Total returns to shareholders of 487% over the past three years. Reported Earnings • Nov 09
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: zł13.4m (up 105% from 3Q 2021). Net income: zł1.54m (up zł2.11m from 3Q 2021). Profit margin: 11% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 99% per year whereas the company’s share price has increased by 96% per year. Reported Earnings • Sep 09
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: zł14.0m (down 3.1% from 2Q 2021). Net income: zł2.73m (down 7.6% from 2Q 2021). Profit margin: 20% (in line with 2Q 2021). Valuation Update With 7 Day Price Move • Jul 20
Investor sentiment improved over the past week After last week's 36% share price gain to zł4.68, the stock trades at a trailing P/E ratio of 65.3x. Average trailing P/E is 26x in the Biotechs industry in Poland. Total returns to shareholders of 374% over the past three years. Valuation Update With 7 Day Price Move • Jul 04
Investor sentiment improved over the past week After last week's 15% share price gain to zł3.64, the stock trades at a trailing P/E ratio of 50.8x. Average trailing P/E is 25x in the Biotechs industry in Poland. Total returns to shareholders of 268% over the past three years. Reported Earnings • May 29
First quarter 2022 earnings released First quarter 2022 results: Revenue: zł8.62m (up 55% from 1Q 2021). Net loss: zł758.0k (loss narrowed 36% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 130% per year but the company’s share price has only increased by 62% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 17
Full year 2021 earnings released: EPS: zł0.067 (vs zł0.071 in FY 2020) Full year 2021 results: EPS: zł0.067 (down from zł0.071 in FY 2020). Revenue: zł41.2m (up 2.5% from FY 2020). Net income: zł4.25m (down 4.3% from FY 2020). Profit margin: 10% (in line with FY 2020). Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has only increased by 67% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment improved over the past week After last week's 27% share price gain to zł3.58, the stock trades at a trailing P/E ratio of 48.5x. Average trailing P/E is 28x in the Biotechs industry in Poland. Total returns to shareholders of 291% over the past three years. Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment deteriorated over the past week After last week's 22% share price decline to zł3.09, the stock trades at a trailing P/E ratio of 41.8x. Average trailing P/E is 33x in the Biotechs industry in Poland. Total returns to shareholders of 268% over the past three years. Valuation Update With 7 Day Price Move • Jan 25
Investor sentiment deteriorated over the past week After last week's 16% share price decline to zł4.15, the stock trades at a trailing P/E ratio of 56.2x. Average trailing P/E is 48x in the Biotechs industry in Poland. Total returns to shareholders of 342% over the past three years. Valuation Update With 7 Day Price Move • Dec 27
Investor sentiment deteriorated over the past week After last week's 16% share price decline to zł3.75, the stock trades at a trailing P/E ratio of 50.8x. Average trailing P/E is 49x in the Biotechs industry in Poland. Total returns to shareholders of 257% over the past three years. Valuation Update With 7 Day Price Move • Nov 30
Investor sentiment deteriorated over the past week After last week's 30% share price decline to zł4.91, the stock trades at a trailing P/E ratio of 66.5x. Average trailing P/E is 52x in the Biotechs industry in Poland. Total returns to shareholders of 350% over the past three years. Reported Earnings • Nov 11
Third quarter 2021 earnings released The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: zł6.55m (down 21% from 3Q 2020). Net loss: zł577.0k (down zł671.0k from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Mar 10
New 90-day high: zł12.15 The company is up 19% from its price of zł10.25 on 10 December 2020. The Polish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 1.0% over the same period. Is New 90 Day High Low • Dec 09
New 90-day low: zł10.80 The company is down 14% from its price of zł12.55 on 10 September 2020. The Polish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period. Reported Earnings • Nov 13
Third quarter 2020 earnings released: EPS zł0.001 The company reported a soft third quarter result with weaker earnings and profit margins, although revenues were improved. Third quarter 2020 results: Revenue: zł8.33m (up 4.3% from 3Q 2019). Net income: zł94.0k (down 73% from 3Q 2019). Profit margin: 1.1% (down from 4.4% in 3Q 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 131% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Jul 08
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced a financing transaction BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) announced private placement of 6,000,000 series R shares on July 7, 2020. The company will issue shares of par value of PLN 0.1 per share without preemptive rights. The transaction has been resolved by the management of the company.